Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kaehler

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 12, 2024
Second opinion and self-efficacy in German skin cancer patientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
Medical Oncology (Northwood, London, England)|April 20, 2016
Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanomaCarmen Loquai, Dagmar Dechent, Marlene Garzarolli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2016
[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]K M Olsson, M Halank, B Egenlauf, et al.
Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Plos One|January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkCaroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 12, 2024
Second opinion and self-efficacy in German skin cancer patientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
Medical Oncology (Northwood, London, England)|April 20, 2016
Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanomaCarmen Loquai, Dagmar Dechent, Marlene Garzarolli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2016
[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]K M Olsson, M Halank, B Egenlauf, et al.
Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Plos One|January 24, 2013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkCaroline J Voskens, Simone M Goldinger, Carmen Loquai, et al.
Pageof 3